- Home
- GRND vs VCEL Comparison
GRND vs VCEL Comparison
Compare GRND & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GRND | VCEL |
|---|---|---|
| Founded | 2009 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.1B |
| IPO Year | 2020 | 1996 |
Fundamental Metrics
Financial Performance| Metric | GRND | VCEL |
|---|---|---|
| Price | $14.64 | $57.38 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | $20.40 | ★ $65.43 |
| AVG Volume (30 Days) | ★ 1.9M | 839.6K |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 158.11 | 60.00 |
| EPS | ★ 0.21 | 0.19 |
| Revenue | ★ $439,898,000.00 | $276,259,000.00 |
| Revenue This Year | $27.79 | $24.98 |
| Revenue Next Year | $13.06 | $15.37 |
| P/E Ratio | ★ $68.81 | $299.79 |
| Revenue Growth | ★ 27.64 | 16.45 |
| 52 Week Low | $9.79 | $28.95 |
| 52 Week High | $18.50 | $59.75 |
Technical Indicators
Market Signals| Indicator | GRND | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 58.10 | 74.24 |
| Support Level | $14.40 | $31.94 |
| Resistance Level | $15.40 | N/A |
| Average True Range (ATR) | 0.62 | 2.65 |
| MACD | 0.21 | 1.52 |
| Stochastic Oscillator | 91.41 | 88.85 |
Price Performance
Historical ComparisonAbout GRND Grindr Inc.
Grindr Inc is a social networking app for gay, bi, trans, and queer people. It is a social network that brings together gay and bisexual men who want to meet other men close to them in a completely discrete and anonymous way, without having to give any personal information or having to fill out a profile with confidential information in order to register.
About VCEL Vericel Corporation
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.